MoonLake Immunotherapeutics

Helix Acquisition Corp (Nasdaq: HLXA), a healthcare-focused special purpose acquisition company that completed its IPO in 2021, filed its annual report on Form 10-K with the SEC on February 17, 2022, covering fiscal year 2021. The SPAC, sponsored by Helix Acquisition Holdings LLC, had announced a proposed business combination with MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases, prior to the filing date. The deal subsequently closed in April 2022, taking MoonLake public under the Nasdaq ticker MLTX. Visit SpacDesk and sign up for full data, filings, and deal analytics on HLXA and hundreds of other SPAC transactions.